Soryuan Bio signed a licensing agreement to develop DB102 new adaptations

,
, December 26, 2019 - Precision Medicine leader So yuan Bio today announced that it has signed a licensing agreement with Rumpus Therapeutics to develop DB102 for the treatment of specific adaptive disorders. Rumpus Therapeutics is licensed by DB102 for research and development and commercialization of certain genetic diseases outside the bio-core areas of tumors, pulmonary hypertension, etc. Under the agreement, Rumpus Therapeutics will pay soot biology including advance payments, exercise options and other expenses, and is expected to bring nearly $100 million in milestone payments and sales credits to Sor dollar biology in the future.Dr. Michael F. Haller, Chief Commercial Officer of Soryuan Bio, said, "Soryuan Bio's acquisition of the world's first innovative late-stage drug with its unique precision medicine platform not only provides a breakthrough in pre-existing conditions, but also contains potential uses and great value in other adaptations. Through the implementation of this agreement, so that in addition to focusing resources to break db102 commitment to the treatment of primary treatment of high-risk diffuse large B cell lymphoma and neuroglioma international clinical trials, but also through cooperation in other diseases to DB102 potential for more timely and full exploration and expansion. This collaboration not only extends the existing product pipeline of Soryuan Bio to new areas of adaptive diseases, but also gives Soryuan Bio the ability to generate revenue before the release of the data for the DB102 clinical first adaptive ENINE study, highlighting the many advantages of SOR's bio-business model". (Drug)